Welcome to our dedicated page for Actinium Pharmac SEC filings (Ticker: ATNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Radiopharma filings can be a maze of clinical acronyms and isotope jargon. Actinium Pharmaceuticals’ SEC documents are no exception—every 8-K on Iomab-B trial data, each 10-Q burn-rate update, and every Form 4 insider trade may move ATNM shares long before an FDA decision. Skip the scavenger hunt. Stock Titan’s AI reads the hundreds of pages for you, flags the nuggets on patient enrollment, isotope supply costs, and cash runway the moment they hit EDGAR.
Wondering how to find the Actinium Pharmaceuticals quarterly earnings report 10-Q filing or need Actinium Pharmaceuticals insider trading Form 4 transactions in real time? Our platform delivers:
- AI-powered summaries that translate biotech language into plain English—perfect for understanding Actinium Pharmaceuticals SEC documents with AI.
- Instant alerts on 8-K material events explained, from interim trial results to manufacturing agreements.
- Side-by-side comparisons of annual report 10-K data, so pipeline spend and cash runway trends stand out.
- Detailed logs of executive stock transactions Form 4, helping you track insider conviction around key readouts.
Use the 10-K to gauge dilution risk, the proxy statement executive compensation details to align incentives, or the Form S-3 shelf registration to anticipate capital raises. Whether you ask, “How to read Actinium’s 10-K annual report?” or “Which insiders bought before the latest AML trial update?”, you’ll find the answer here—all filings, all forms, always updated, already explained.
The Vanguard Group has filed Amendment No. 1 to Schedule 13G for Actinium Pharmaceuticals (ATNM), triggered by the 30 June 2025 reportable event. The filing discloses 1,371,840 ATNM common shares beneficially owned, equal to 4.39 % of the outstanding class, placing Vanguard below the 5 % threshold noted in Item 5.
According to Item 4, Vanguard holds no voting power—sole or shared—but retains dispositive authority over nearly all of the shares (sole: 1,362,947; shared: 8,893). Vanguard is filing in its capacity as an investment adviser (Rule 13d-1(b)(1)(ii)(E)); the ownership is on behalf of its advisory clients, none of which individually own more than 5 %. Certification in Item 10 confirms the stake is held in the ordinary course of business and not for the purpose of influencing control of ATNM.
FAQ
What is the current stock price of Actinium Pharmac (ATNM)?
What is the market cap of Actinium Pharmac (ATNM)?
What is Actinium Pharmaceuticals?
What are the key product candidates developed by Actinium?
How does Actinium’s technology work?
What market need does Actinium address?
How is the company positioned within the competitive landscape?
What role does Iomab-B play in patient treatment?
How does Actinium ensure the safety of its therapies?
What experts and partnerships support Actinium’s work?
